The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97 - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Jul;44(11):1552-8.
doi: 10.1016/j.ejca.2008.03.013. Epub 2008 Apr 16.
Affiliations
- PMID: 18424129
- DOI: 10.1016/j.ejca.2008.03.013
Randomized Controlled Trial
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97
Matthias Schmidt et al. Eur J Cancer. 2008 Jul.
Abstract
Aim/purpose: (123)I-meta-iodobenzylguanidine ((123)I-mIBG) scintigraphy is well established for staging and evaluation of response in children with high-risk neuroblastoma but its prognostic value in highly intensive first-line treatment protocols is uncertain. The presence of any (123)I-mIBG positive tumour tissue was correlated with event-free survival (EFS) and overall survival (OS).
Patients and methods: The prognostic impact of residual (123)I-mIBG uptake into the primary tumour and metastases for predicting outcome in 113 stage 4 neuroblastoma patients >1 year of the German Neuroblastoma Trial NB97 was assessed using a univariate log-rank test and multivariate Cox regression analysis.
Results: All patients had (123)I-mIBG positive disease at initial staging. After four courses of induction chemotherapy, 71% of patients were still (123)I-mIBG positive for the primary tumour and 61% for metastases. After six courses, 39% of patients had (123)I-mIBG uptake by the primary tumour and 45% residual (123)I-mIBG positive metastatic disease. The (123)I-mIBG status of the primary tumour site had no bearing on outcome. Residual (123)I-mIBG positive metastatic disease after four (3-y-EFS 25.7+/-5.3% versus 55.9+/-7.6%, p=0.009; 3-y-OS 49.8+/-6.1% versus 65.0+/-7.3%; p=0.021) and after six chemotherapy cycles (3-y-EFS 27.5+/-6.2% versus 47.4+/-6.4%, p=0.011; 3-y-OS 50.5+/-7.1% vs 60.0+/-6.4%, p=0.031) was associated with poor outcome.
Conclusion: Functional imaging with (123)I-mIBG scintigraphy can identify poor responders with any persistent metastatic (123)I-mIBG uptake who are at a high risk of disease relapse. (123)I-mIBG response of the primary tumour site had no bearing on outcome.
Similar articles
- Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F, Dietlein M, Berthold F, Schmidt M. Decarolis B, et al. J Clin Oncol. 2013 Mar 1;31(7):944-51. doi: 10.1200/JCO.2012.45.8794. Epub 2013 Jan 22. J Clin Oncol. 2013. PMID: 23341514 - Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Conte M, Villavecchia GP, Garaventa A, Lanino E, De Bernardi B, Scopinaro G. Claudiani F, et al. Q J Nucl Med. 1995 Dec;39(4 Suppl 1):21-4. Q J Nucl Med. 1995. PMID: 9002744 - [MIBG scintigraphy in neuroblastoma: something more than an image].
Díez Jiménez L, Mitjavila Casanovas M. Díez Jiménez L, et al. Rev Esp Med Nucl. 2006 Mar-Apr;25(2):118-43. doi: 10.1157/13086257. Rev Esp Med Nucl. 2006. PMID: 16759621 Review. Spanish. No abstract available.
Cited by
- Theranostic Diagnostics.
Ali MU, Chaudhary BN, Panja S, Gendelman HE. Ali MU, et al. Results Probl Cell Differ. 2024;73:551-578. doi: 10.1007/978-3-031-62036-2_22. Results Probl Cell Differ. 2024. PMID: 39242393 Review. - Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy.
Gorostegui M, Muñoz JP, Perez-Jaume S, Simao-Rafael M, Larrosa C, Garraus M, Salvador N, Lavarino C, Krauel L, Mañe S, Castañeda A, Mora J. Gorostegui M, et al. Cancers (Basel). 2024 Apr 29;16(9):1735. doi: 10.3390/cancers16091735. Cancers (Basel). 2024. PMID: 38730688 Free PMC article. - Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes.
Muñoz JP, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda A, Garraus M, Lopez-Miralles S, Mora J. Muñoz JP, et al. Cancers (Basel). 2023 Oct 3;15(19):4837. doi: 10.3390/cancers15194837. Cancers (Basel). 2023. PMID: 37835531 Free PMC article. - Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss SD, Yu AL, London WB, Park JR, Yanik GA, Naranjo A. Streby KA, et al. Pediatr Blood Cancer. 2023 Aug;70(8):e30418. doi: 10.1002/pbc.30418. Epub 2023 May 18. Pediatr Blood Cancer. 2023. PMID: 37199022 Free PMC article. Clinical Trial. - Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report.
Mora J, Castañeda A, Gorostegui M, Varo A, Perez-Jaume S, Simao M, Muñoz JP, Garraus M, Larrosa C, Salvador N, Lavarino C, Krauel L, Mañe S. Mora J, et al. Cancers (Basel). 2023 Apr 28;15(9):2535. doi: 10.3390/cancers15092535. Cancers (Basel). 2023. PMID: 37174002 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical